• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Royalty Pharma plc

    5/16/25 4:24:25 PM ET
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPRX alert in real time by email
    S-8 1 dp228790_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on May 16, 2025

     

                                                                                                                                                                                                                           Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    ______________________

     

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    ______________________

     

    Royalty Pharma plc

    (Exact Name of Registrant as Specified in Its Charter)

     

    England and Wales   98-1535773

    (State or Other Jurisdiction

    of Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

     

    110 East 59th Street
    New York, New York 10022

    (Address of Principal Executive Offices)  (Zip Code)

     

    Royalty Pharma plc 2025 Equity Incentive Plan

    (Full Title of the Plans)

    ______________________

     

    Pablo Legorreta

    Chief Executive Officer

    Royalty Pharma plc
    110 East 59th Street
    New York, New York 10022

    (Name and Address of Agent For Service)

     

    (212) 883-0200

    (Telephone Number, including area code, of agent for service)

     

    ______________________

     

    Copies to:

     

    Richard D. Truesdell, Jr. Esq.

    Davis Polk & Wardwell LLP

    450 Lexington Avenue

    New York, New York 10017

    (212) 450-4000

     

    ______________________

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.            ¨

     

     

    PART I

     

    Information Required in the Section 10(a) Prospectus

     

    The information specified in Item 1 and Item 2 of Part I is omitted from this filing and is included in documents sent or provided to participants of the Royalty Pharma plc 2025 Equity Incentive Plan covered by this Registration Statement on Form S-8 (this “Registration Statement”) pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

     

     

     

    PART II

     

    Information Required in the Registration Statement

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act, and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:  

     

    (a)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 12, 2025 (the “Annual Report”);  

     

    (b)the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on May 8, 2025;  

     

    (c)the Registrant’s Current Reports on Form 8-K filed with the Commission on January 10, 2025 (excluding the information disclosed pursuant to Item 7.01 and Exhibits 99.1, 99.2 and 99.3 thereto), April 10, 2025, April 11, 2025 and May 12, 2025.

     

    (d)all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant's Annual Report referred to in (a) above; and

     

    (e)the Registrant’s Registration Statement on Form 8-A dated June 15, 2020, including any amendments or reports filed for the purpose of updating such description.

     

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K prior or subsequent to the filing of this Registration Statement shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    We have entered into indemnification agreements with our directors and executive officers to indemnify them to the maximum extent allowed under applicable law. These agreements indemnify these individuals against certain costs, charges, losses, liabilities, damages and expenses incurred by such director or officer in the execution or discharge of his or her duties or the exercise of his or her powers or otherwise in relation to or in connection with his or her duties, powers or office. These agreements do not indemnify our directors against any liability attaching to such individuals in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he or she is a director, which would be rendered void under the Companies Act.

     

    The Company also maintains directors and officers insurance to insure such persons against certain liabilities.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of our Articles, agreement, vote of shareholders or disinterested directors or otherwise

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

     

     

    Item 8. Exhibits.

     

    Exhibit   Incorporated by Reference Filed
    Number Exhibit Description Form File No. Exhibit Filing Date Herewith
                 
    4.1 Articles of Association of the Registrant. 8-K 001-39329 3.1 June 19, 2020  
    4.2 Form of Registrant's Class A Ordinary Share Certificate. S-1/A 333-238632 4.1 June 11, 2020  
    5.1 Opinion of Davis Polk & Wardwell London LLP         X
    23.1 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.         X
    23.2 Consent of Davis Polk & Wardwell London LLP (contained in Exhibit 5.1).         X
    24.1 Power of Attorney (included on the signature page of this Registration Statement).         X
    99.1 Royalty Pharma plc 2025 Equity Incentive Plan.         X
    107.1 Filing Fee Table         X

     

     

    Item 9. Undertakings.

     

    (a) The Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

     

    (iii) To include any material information with respect to the plan not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

     

    provided, however, that the undertakings set forth in paragraphs (a)(1)(i)and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act, that are incorporated by reference in this Registration Statement;

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering;

     

    (b) The undersigned Registrant hereby undertakes that, for the purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, New York, on this 16th day of May, 2025.

     

          ROYALTY PHARMA PLC
           
    Date: May 16, 2025   /s/ Pablo Legorreta
          Pablo Legorreta
          Chief Executive Officer
           

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned officers and directors of Registrant do hereby constitute and appoint Pablo Legorreta, Terrance Coyne and George Lloyd and each of them, as his or her true and lawful attorneys-in-fact and agents with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement.  Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys and agents, or any one of them, shall do or cause to be done by virtue hereof.  

     

    IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

     

    Signature   Title   Date
    /s/ Pablo Legorreta   Chairman of the Board, Director & Chief Executive Officer   May 16, 2025
    Pablo Legorreta   (Principal Executive Officer)    
    /s/ Terrance Coyne   Executive Vice President & Chief Financial Officer   May 16, 2025
    Terrance Coyne   (Principal Financial Officer and Principal Accounting Officer)    
    /s/ Bonnie Bassler   Director   May 16, 2025
    Bonnie Bassler        
    /s/ Vlad Coric   Director   May 16, 2025
    Vlad Coric        
    /s/ Errol De Souza   Director   May 16, 2025
    Errol De Souza        
    /s/ Catherine Engelbert   Director   May 16, 2025
    Catherine Engelbert        
    /s/ Henry Fernandez   Director   May 16, 2025
    Henry Fernandez        
    /s/ David Hodgson   Director   May 16, 2025
    David Hodgson        
    /s/ Ted Love   Director   May 16, 2025
    Ted Love        
    /s/ Gregory Norden   Director   May 16, 2025
    Gregory Norden        

     

     

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE

     

    Under the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Royalty Pharma plc has signed this registration statement or amendment thereto on May 16, 2025.

     

           
      Authorized U.S. Representative
         
      By: /s/ Pablo Legorreta
        Name:

    Pablo Legorreta 

        Title: Chief Executive Officer

     

     

     

     

     

    Get the next $RPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPRX

    DatePrice TargetRatingAnalyst
    5/16/2025$51.00Overweight
    Morgan Stanley
    6/3/2024$28.00Buy → Neutral
    UBS
    6/14/2022$47.00Buy
    UBS
    5/13/2022$53.00Sector Outperform
    Scotiabank
    4/27/2022$56.00Buy
    Goldman
    4/14/2022$50.00Neutral → Overweight
    JP Morgan
    4/6/2022$48.00Overweight
    Morgan Stanley
    10/29/2021$50.00Neutral → Buy
    Citigroup
    More analyst ratings

    $RPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on Royalty Pharma with a new price target

      Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

      5/16/25 8:05:49 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma downgraded by UBS with a new price target

      UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00

      6/3/24 9:17:33 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS resumed coverage on Royalty Pharma with a new price target

      UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00

      6/14/22 7:27:46 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Royalty Pharma plc

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      11/8/24 3:15:49 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Royalty Pharma plc

      SC 13D/A - Royalty Pharma plc (0001802768) (Subject)

      7/29/24 4:30:11 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Royalty Pharma plc (Amendment)

      SC 13G/A - Royalty Pharma plc (0001802768) (Subject)

      2/13/24 10:17:30 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Financials

    Live finance-specific insights

    See more
    • Royalty Pharma Completes the Acquisition of Its External Manager

      NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ("RP Management"). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction. "The completion of the internalization marks an exciting new chapter for Royalty Pharma," said Pablo Legorreta, founder and Chief Executive Officer. "It reinforces our commitment to transparency, accountability and long-term growth, while better positioning us to fund the significant capital needs and exciting innovation happening in the life sciences indu

      5/16/25 4:30:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

      Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsRoyalty Pharma's diversified royalty portfolio to be combined with intellectual capital and investment platform of the Manager to advance shareholder value creation NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that sharehold

      5/12/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Reports First Quarter 2025 Results

      Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. "Our business momentum continued in the first quarter of 2025 as we delivered double-digit growth in Portfolio Receipts and raised our financial guidance," said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. "Guided by our dynamic capital allocat

      5/8/25 7:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon

      4/8/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

      NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg

      7/24/24 8:30:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

      NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma's Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenure at Verisk, he led their migration to the cloud, mainframe modernization strategy and Data Governance and Data Strategy Team. Prior to Verisk, Mr. Schneider held senior IT leadership roles at Moody

      9/21/23 8:25:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    SEC Filings

    See more
    • SEC Form S-8 filed by Royalty Pharma plc

      S-8 - Royalty Pharma plc (0001802768) (Filer)

      5/16/25 4:24:25 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Royalty Pharma plc

      8-K - Royalty Pharma plc (0001802768) (Filer)

      5/12/25 4:06:55 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Royalty Pharma plc

      SCHEDULE 13G/A - Royalty Pharma plc (0001802768) (Subject)

      5/12/25 10:39:51 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Royalty Pharma Completes the Acquisition of Its External Manager

      NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC ("RP Management"). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction. "The completion of the internalization marks an exciting new chapter for Royalty Pharma," said Pablo Legorreta, founder and Chief Executive Officer. "It reinforces our commitment to transparency, accountability and long-term growth, while better positioning us to fund the significant capital needs and exciting innovation happening in the life sciences indu

      5/16/25 4:30:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma to Present at Upcoming Investor Conferences

      NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET / 2:20 p.m. PTRBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET The webcasts will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation

      5/13/25 8:15:00 AM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

      Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsRoyalty Pharma's diversified royalty portfolio to be combined with intellectual capital and investment platform of the Manager to advance shareholder value creation NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that sharehold

      5/12/25 4:15:00 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Engelbert Catherine M. was granted 7,614 units of Class A Ordinary Shares, increasing direct ownership by 17% to 51,128 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/15/25 5:41:32 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Norden Gregory was granted 7,614 units of Class A Ordinary Shares, increasing direct ownership by 10% to 83,688 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/14/25 5:12:13 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Love Ted W was granted 7,614 units of Class A Ordinary Shares, increasing direct ownership by 16% to 53,848 units (SEC Form 4)

      4 - Royalty Pharma plc (0001802768) (Issuer)

      5/14/25 5:11:13 PM ET
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care